EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Vistin Pharma ASA's Enterprise Value is kr888.8 Mil.
Vistin Pharma ASA's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr51.3 Mil. Therefore, Vistin Pharma ASA's EV-to-FCF for today is 17.31.
The historical rank and industry rank for Vistin Pharma ASA's EV-to-FCF or its related term are showing as below:
OSL:VISTN'
s EV-to-FCF Range Over the Past 10 Years
Min: -45.33 Med: -1.26 Max: 61.05
Current: 17.31
During the past 13 years, the highest EV-to-FCF of Vistin Pharma ASA was 61.05. The lowest was -45.33. And the median was -1.26.
OSL:VISTN's EV-to-FCF is ranked better than 58.97% of 563
companies
in the Drug Manufacturers industry
Industry Median: 20.85
vs OSL:VISTN: 17.31
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vistin Pharma ASA's PE Ratio (TTM) for today is calculated as:
Vistin Pharma ASA's share price for today is kr20.40.
Vistin Pharma ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.680.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vistin Pharma ASA EV-to-FCF Related Terms
Vistin Pharma ASA EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Vistin Pharma ASA's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:VISTN vs ZTS, UTHR, VTRS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's EV-to-FCF falls into.
Vistin Pharma ASA's current Enterprise Value is kr888.8 Mil.
Vistin Pharma ASA's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr51.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistin Pharma ASA (OSL:VISTN) has a EV-to-FCF of 17.31 as of Jul. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vistin Pharma ASA and its competitors. According to the industry distribution chart, Vistin Pharma ASA ranks #231 out of 563 companies in the Drug Manufacturers industry, placing it in the top 41%.
Is Vistin Pharma ASA's EV-to-FCF too high?
Vistin Pharma ASA's current EV-to-FCF is 17.31. The Drug Manufacturers industry median EV-to-FCF is 20.85. Vistin Pharma ASA's value of 17.31 is 17% below this industry median. Based on the distribution chart, Vistin Pharma ASA ranks #231 out of 563 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vistin Pharma ASA has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #231 out of 563 companies for EV-to-FCF. This puts Vistin Pharma ASA in the upper half of its industry. The industry median EV-to-FCF is 20.85. Vistin Pharma ASA's value of 17.31 is 17% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.85, based on 563 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistin Pharma ASA's current EV-to-FCF of 17.31 is 17% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current EV-to-FCF is 17.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (OSL:VISTN) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.61, compared to a current price of kr20.40 — trading 20.3% below its estimated fair value. The current EV-to-FCF is 17.31 and 17% below the Drug Manufacturers industry median of 20.85. Vistin Pharma ASA's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Vistin Pharma ASA (OSL:VISTN), the current EV-to-FCF is 17.31 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (OSL:VISTN) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.40 is trading 20.3% below its estimated GF Value™ of kr25.61.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for OSL:VISTN:
EV-to-FCF: 17.31
GF Value™: kr25.61 vs. price of kr20.40 (20.3% below fair value)
Industry Position: 17% below the Drug Manufacturers median (#231 of 563)
No single metric tells the full story. See the OSL:VISTN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
80GF Score
Get the complete analysis for OSL:VISTN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:VISTN has been successfully added to your 
